Physician profile
Sara Matar
NPI 1376959494
$1,750.42
in general payments reported to CMS, 2019-2025
19 companies · $660 in 2025
The $660 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $221 · 2020: $123 · 2021: $11.92 · 2022: $137 · 2023: $61.48 · 2024: $536 · 2025: $660.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $854 · Education: $404.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $854.12 |
| Education | $403.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $248.70 | 2020-2024 | Tagrisso |
| Janssen Biotech, INC. | $238.19 | 2025 | Carvykti, Rybrevant, Talvey |
| Aveo Pharmaceuticals, INC. | $204.49 | 2022-2025 | |
| Glaxosmithkline, LLC. | $161.20 | 2025 | Jemperli, Blenrep, Ojjaara |
| Genentech USA, INC. | $143.37 | 2024-2025 | Polivy, Columvi, Venclexta |
| E.R. Squibb & Sons, L.L.C. | $110.76 | 2019 | |
| Alexion Pharmaceuticals, INC. | $109.98 | 2019 | |
| Daiichi Sankyo INC. | $100.46 | 2022-2024 | Enhertu |
| Pfizer INC. | $99.99 | 2024 | |
| Sanofi-Aventis U.S. LLC | $90.95 | 2024 | |
| Abbvie INC. | $42.90 | 2025 | |
| Eisai INC. | $40.00 | 2023 | |
| Genzyme Corporation | $35.59 | 2025 | |
| Gilead Sciences, INC. | $27.12 | 2021-2024 | |
| Kite Pharma, INC. | $23.92 | 2025 | Yescarta |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $21.48 | 2023 | Blincyto |
| Novartis Pharmaceuticals Corporation | $20.31 | 2025 | |
| Tactile Systems Technology INC | $15.60 | 2024 | Entre Plus, Flexitouch Plus |
| Stemline Therapeutics INC. | $15.41 | 2024 | Orserdu |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sara Matar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.